• Publications
  • Influence
Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway
Imatinib (IM) is highly effective in treatment of chronic myeloid leukemia (CML) but does not eliminate minimal residual disease (MRD), which remains a potential source of relapse. IM treatmentExpand
  • 25
  • 1
THE EXPRESS OF HIGH ENDOTHELIAL VENULES IN THE ENDOMETRIUM